Literature DB >> 9620884

Human alpha-galactosidase A: glycosylation site 3 is essential for enzyme solubility.

Y A Ioannou1, K M Zeidner, M E Grace, R J Desnick.   

Abstract

Human alpha-galactosidase A (EC 3.2.1.22; alpha-Gal A) is the homodimeric glycoprotein that hydrolyses the terminal alpha-galactosyl moieties from glycolipids and glycoproteins. The type, site occupancy and function of the N-linked oligosaccharide chains on this lysosomal hydrolase were determined. Endoglycosidase treatment of the purified recombinant enzyme and mutagenesis studies indicated that three (Asn-139, Asn-192 and Asn-215) of the four potential N-glycosylation consensus sequences were occupied by complex, high-mannose and hybrid-type oligosaccharides respectively. When expressed in COS-1 cells, glycoforms with glycosylation site 1 or 2 obliterated had more than 70% of wild-type activity, and both glycoforms were secreted. In contrast, the glycoform with only site 3 eliminated had decreased activity (less than 40%); little, if any, was secreted. Expressed mutant glycoforms in which site 3 and site 1 or 2 were obliterated had little, if any, intracellular or secreted enzymic activity, and immunofluorescence microscopy revealed that the expressed mutant glycoforms were retained in the endoplasmic reticulum, presumably where they were degraded. Thus glycosylation at site 3 was crucial to the formation of soluble, active enzyme, as well as transport to the lysosome. Absence of the site 3 hybrid-type oligosaccharide exposed an adjacent, normally protected, hydrophobic region, resulting in aggregation of the enzyme polypeptide in the endoplasmic reticulum. In support of this concept, endoglycosidase H-treated enzyme or mannose-terminated enzyme expressed in Autographa californica cells also aggregated when concentrated, emphasizing that site 3 occupancy by a hybrid-type oligosaccharide was required for enzyme solubility.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9620884      PMCID: PMC1219542          DOI: 10.1042/bj3320789

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  29 in total

1.  Pilot scale purification of alpha-galactosidase A from Cohn fraction IV-1 of human plasma.

Authors:  D F Bishop; D E Wampler; J T Sgouris; R J Bonefeld; D K Anderson; M C Hawley; C C Sweeley
Journal:  Biochim Biophys Acta       Date:  1978-05-11

2.  Fabry disease: fourteen alpha-galactosidase A mutations in unrelated families from the United Kingdom and other European countries.

Authors:  J P Davies; C M Eng; J A Hill; S Malcolm; K MacDermot; B Winchester; R J Desnick
Journal:  Eur J Hum Genet       Date:  1996       Impact factor: 4.246

3.  Nucleotide sequence of the human alpha-galactosidase A gene.

Authors:  R Kornreich; R J Desnick; D F Bishop
Journal:  Nucleic Acids Res       Date:  1989-04-25       Impact factor: 16.971

4.  Conformational parameters for amino acids in helical, beta-sheet, and random coil regions calculated from proteins.

Authors:  P Y Chou; G D Fasman
Journal:  Biochemistry       Date:  1974-01-15       Impact factor: 3.162

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  Synthesis and processing of alpha-galactosidase A in human fibroblasts. Evidence for different mutations in Fabry disease.

Authors:  P Lemansky; D F Bishop; R J Desnick; A Hasilik; K von Figura
Journal:  J Biol Chem       Date:  1987-02-15       Impact factor: 5.157

7.  Human alpha-galactosidase A: nucleotide sequence of a cDNA clone encoding the mature enzyme.

Authors:  D F Bishop; D H Calhoun; H S Bernstein; P Hantzopoulos; M Quinn; R J Desnick
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

8.  The spectrum of anionic oligosaccharides released by endo-beta-N-acetylglucosaminidase H from glycoproteins. Structural studies and interactions with the phosphomannosyl receptor.

Authors:  A Varki; S Kornfeld
Journal:  J Biol Chem       Date:  1983-03-10       Impact factor: 5.157

9.  Affinity purification of alpha-galactosidase A from human spleen, placenta, and plasma with elimination of pyrogen contamination. Properties of the purified splenic enzyme compared to other forms.

Authors:  D F Bishop; R J Desnick
Journal:  J Biol Chem       Date:  1981-02-10       Impact factor: 5.157

10.  Structural studies of phosphorylated high mannose-type oligosaccharides.

Authors:  A Varki; S Kornfeld
Journal:  J Biol Chem       Date:  1980-11-25       Impact factor: 5.157

View more
  29 in total

Review 1.  Fabry disease, enzyme replacement therapy and the significance of antibody responses.

Authors:  Patrick B Deegan
Journal:  J Inherit Metab Dis       Date:  2011-10-25       Impact factor: 4.982

Review 2.  Structural determinants of protein folding.

Authors:  Tse Siang Kang; R Manjunatha Kini
Journal:  Cell Mol Life Sci       Date:  2009-04-15       Impact factor: 9.261

Review 3.  Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy.

Authors:  Ricardo J Solá; Kai Griebenow
Journal:  BioDrugs       Date:  2010-02-01       Impact factor: 5.807

4.  Interrelationship of steric stabilization and self-crowding of a glycosylated protein.

Authors:  R Høiberg-Nielsen; P Westh; L K Skov; L Arleth
Journal:  Biophys J       Date:  2009-09-02       Impact factor: 4.033

5.  Characterization of a long-chain α-galactosidase from Papiliotrema flavescens.

Authors:  Barbora Stratilová; Jaroslav Klaudiny; Pavel Řehulka; Eva Stratilová; Csilla Mészárosová; Soňa Garajová; Barbora Pavlatovská; Helena Řehulková; Stanislav Kozmon; Sergej Šesták; Zuzana Firáková; Renáta Vadkertiová
Journal:  World J Microbiol Biotechnol       Date:  2018-01-04       Impact factor: 3.312

6.  Comparison of intracellular and secretion-based strategies for production of human α-galactosidase A in the filamentous fungus Trichoderma reesei.

Authors:  Wesley Smith; Jussi Jäntti; Merja Oja; Markku Saloheimo
Journal:  BMC Biotechnol       Date:  2014-10-27       Impact factor: 2.563

7.  Human α-L-iduronidase uses its own N-glycan as a substrate-binding and catalytic module.

Authors:  Nobuo Maita; Takahiro Tsukimura; Takako Taniguchi; Seiji Saito; Kazuki Ohno; Hisaaki Taniguchi; Hitoshi Sakuraba
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-19       Impact factor: 11.205

Review 8.  Effects of glycosylation on the stability of protein pharmaceuticals.

Authors:  Ricardo J Solá; Kai Griebenow
Journal:  J Pharm Sci       Date:  2009-04       Impact factor: 3.534

9.  Role of glycosylation in conformational stability, activity, macromolecular interaction and immunogenicity of recombinant human factor VIII.

Authors:  Matthew P Kosloski; Razvan D Miclea; Sathy V Balu-Iyer
Journal:  AAPS J       Date:  2009-06-05       Impact factor: 4.009

10.  The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines.

Authors:  E R Benjamin; J J Flanagan; A Schilling; H H Chang; L Agarwal; E Katz; X Wu; C Pine; B Wustman; R J Desnick; D J Lockhart; K J Valenzano
Journal:  J Inherit Metab Dis       Date:  2009-04-18       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.